Dr. Amar Singh, Erlanger urologist who focuses on Urological Oncology and Robotic Minimally Invasive Surgery, performed the first Focal One Robotic HIFU procedure in Tennessee on Tuesday
Erlanger Urology, a regional leader for prostate cancer and kidney-sparing surgeries, was the first in Tennessee to perform the noninvasive Focal One Robotic High Intensity Focused Ultrasound (HIFU) procedure for prostate cancer.
Dr. Amar Singh, Erlanger Urologist who focuses on Urological Oncology and Robotic Minimally Invasive Surgery, performed three of these breakthrough procedures on Tuesday.
Focal One Robotic HIFU is the most advanced in precisely targeted ablation of diseased prostate tissue. This technology combines real-time ultrasound image guidance with magnetic resonance imaging (MRI) and biopsy data presented in 3D. Using a probe, the doctor navigates to the tumor in real-time, directs high-speed ultrasound energy at the target area, and ablates only the diseased portion of the prostate without any incisions. Robotic HIFU is offered to patients with localized prostate cancer.
Dr. Singh said, “We are proud to be first in Tennessee, leading the technological advancements for more precise treatment of prostate cancer. This technology allows us to treat early detected prostate cancer focally through exacting precision. Through this focused approach, we can maximize the cancer treatment while avoiding typical sexual and urinary side effects which impact the quality of life.”
The fusion of these technologies enables urologists to establish more precise contours around the cancerous tumor than was possible in the past. Critically, they can then ablate a smaller portion of the prostate, which lessens the damage to surrounding healthy tissue and minimizes the risk of side effects of urinary incontinence and erectile dysfunction for patients, commonly associated with radical prostatectomy and radiation.
Dr. Amar Singh and team performed the first Focal One Robotic HIFU procedure in Tennessee on Tuesday